German Adjuvant Intergroup Node Positive (GAIN) study: A phase III trial to compare IDD-ETC versus EC-TX in patients with node-positive primary breast cancer—Final efficacy analysis.
Volker Jochen Moebus
Honoraria - Amgen; Celgene; Roche
Research Funding - Amgen; Roche
Gunter Von Minckwitz
Consultant or Advisory Role - Amgen; Roche
Honoraria - Amgen; Roche
Research Funding - Amgen; Bristol-Myers Squibb; Roche
Christian Jackisch
No relevant relationships to disclose
Hans-Joachim Lueck
Honoraria - Amgen; Novartis; Roche
Andreas Schneeweiss
Consultant or Advisory Role - Celgene; Medac; Roche
Honoraria - AstraZeneca; Celgene; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - Celgene; Roche
Hans Tesch
Honoraria - Amgen
Dirk Elling
No relevant relationships to disclose
Nadia Harbeck
Consultant or Advisory Role - Celgene; Roche
Honoraria - Celgene; Novartis; Roche
Research Funding - Amgen; Celgene; Genomic Health; Roche; Teva
Bettina Conrad
No relevant relationships to disclose
Tanja Fehm
No relevant relationships to disclose
Jens Bodo Huober
Consultant or Advisory Role - GlaxoSmithKline; Roche; Sanofi
Honoraria - Roche
Research Funding - GlaxoSmithKline
Volkmar Müller
Consultant or Advisory Role - Amgen; Celgene; Roche
Honoraria - Amgen; Celgene; Janssen-Cilag; Pierre Fabre Medicament; Roche
Ingo Bauerfeind
Honoraria - Bristol-Myers Squibb
Marcus Schmidt
Consultant or Advisory Role - Roche
Stock Ownership - Roche
Honoraria - Roche
Sibylle Loibl
Honoraria - Amgen; Roche
Valentina Nekljudova
No relevant relationships to disclose
Michael Untch
No relevant relationships to disclose
Christoph Thomssen
Honoraria - Amgen; Roche